These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 28754590)

  • 1. Telmisartan mitigates hyperglycemia-induced vascular inflammation by increasing GSK3β-Ser
    Song KH; Bae SJ; Chang J; Park JH; Jo I; Cho KW; Cho DH
    Biochem Biophys Res Commun; 2017 Sep; 491(4):903-911. PubMed ID: 28754590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Telmisartan attenuates hyperglycemia-exacerbated VCAM-1 expression and monocytes adhesion in TNFα-stimulated endothelial cells by inhibiting IKKβ expression.
    Song KH; Park JH; Jo I; Park JY; Seo J; Kim SA; Cho DH
    Vascul Pharmacol; 2016 Mar; 78():43-52. PubMed ID: 26455386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telmisartan Inhibits Nitric Oxide Production and Vessel Relaxation via Protein Phosphatase 2A-mediated Endothelial NO Synthase-Ser
    Cho DH
    J Korean Med Sci; 2019 Nov; 34(42):e266. PubMed ID: 31674157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telmisartan inhibits vasoconstriction via PPARγ-dependent expression and activation of endothelial nitric oxide synthase.
    Yuen CY; Wong WT; Tian XY; Wong SL; Lau CW; Yu J; Tomlinson B; Yao X; Huang Y
    Cardiovasc Res; 2011 Apr; 90(1):122-9. PubMed ID: 21156825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telmisartan inhibits cytokine-induced nuclear factor-kappaB activation independently of the peroxisome proliferator-activated receptor-gamma.
    Nakano A; Hattori Y; Aoki C; Jojima T; Kasai K
    Hypertens Res; 2009 Sep; 32(9):765-9. PubMed ID: 19590508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of tumor necrosis factor-alpha-induced interleukin-6 expression by telmisartan through cross-talk of peroxisome proliferator-activated receptor-gamma with nuclear factor kappaB and CCAAT/enhancer-binding protein-beta.
    Tian Q; Miyazaki R; Ichiki T; Imayama I; Inanaga K; Ohtsubo H; Yano K; Takeda K; Sunagawa K
    Hypertension; 2009 May; 53(5):798-804. PubMed ID: 19289654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Telmisartan inhibits vascular dysfunction and inflammation via activation of peroxisome proliferator-activated receptor-γ in subtotal nephrectomized rat.
    Toba H; Tojo C; Wang J; Noda K; Kobara M; Nakata T
    Eur J Pharmacol; 2012 Jun; 685(1-3):91-8. PubMed ID: 22314223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-inflammatory and anti-oxidant properties of telmisartan in cultured human umbilical vein endothelial cells.
    Cianchetti S; Del Fiorentino A; Colognato R; Di Stefano R; Franzoni F; Pedrinelli R
    Atherosclerosis; 2008 May; 198(1):22-8. PubMed ID: 17950296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Luteolin protects against vascular inflammation in mice and TNF-alpha-induced monocyte adhesion to endothelial cells via suppressing IΚBα/NF-κB signaling pathway.
    Jia Z; Nallasamy P; Liu D; Shah H; Li JZ; Chitrakar R; Si H; McCormick J; Zhu H; Zhen W; Li Y
    J Nutr Biochem; 2015 Mar; 26(3):293-302. PubMed ID: 25577468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Telmisartan prevents VCAM-1 induction and monocytic cell adhesion to endothelium exposed to non-uniform shear stress and TNF-α.
    Cicha I; Urschel K; Daniel WG; Garlichs CD
    Clin Hemorheol Microcirc; 2011; 48(1):65-73. PubMed ID: 21876235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telmisartan inhibits advanced glycation end products (AGEs)-elicited endothelial cell injury by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gammaactivation.
    Yamagishi S; Matsui T; Nakamura K; Takeuchi M; Inoue H
    Protein Pept Lett; 2008; 15(8):850-3. PubMed ID: 18855759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Telmisartan protects against vascular dysfunction with peroxisome proliferator-activated receptor-γ activation in hypertensive 5/6 nephrectomized rats.
    Toba H; Wang J; Ohigashi M; Kobara M; Nakata T
    Pharmacology; 2013; 92(5-6):265-75. PubMed ID: 24281041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telmisartan inhibits the proinflammatory effects of homocysteine on human endothelial cells through activation of the peroxisome proliferator-activated receptor-δ pathway.
    Xu S; Song H; Huang M; Wang K; Xu C; Xie L
    Int J Mol Med; 2014 Sep; 34(3):828-34. PubMed ID: 24994548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endothelial PPAR-γ provides vascular protection from IL-1β-induced oxidative stress.
    Mukohda M; Stump M; Ketsawatsomkron P; Hu C; Quelle FW; Sigmund CD
    Am J Physiol Heart Circ Physiol; 2016 Jan; 310(1):H39-48. PubMed ID: 26566726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Telmisartan prevents angiotensin II-induced endothelial dysfunction in rabbit aorta via activating HGF/Met system and PPARγ pathway.
    Hu ZP; Fang XL; Qian HY; Fang N; Wang BN; Wang Y
    Fundam Clin Pharmacol; 2014 Oct; 28(5):501-11. PubMed ID: 24188213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telmisartan increases hepatic glucose production via protein kinase C ζ-dependent insulin receptor substrate-1 phosphorylation in HepG2 cells and mouse liver.
    Cho KW; Cho DH
    Yeungnam Univ J Med; 2019 Jan; 36(1):26-35. PubMed ID: 31620609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telmisartan protects against diabetic vascular complications in a mouse model of obesity and type 2 diabetes, partially through peroxisome proliferator activated receptor-γ-dependent activity.
    Toyama K; Nakamura T; Kataoka K; Yasuda O; Fukuda M; Tokutomi Y; Dong YF; Ogawa H; Kim-Mitsuyama S
    Biochem Biophys Res Commun; 2011 Jul; 410(3):508-13. PubMed ID: 21679694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cognitive deficit in amyloid-beta-injected mice was improved by pretreatment with a low dose of telmisartan partly because of peroxisome proliferator-activated receptor-gamma activation.
    Tsukuda K; Mogi M; Iwanami J; Min LJ; Sakata A; Jing F; Iwai M; Horiuchi M
    Hypertension; 2009 Oct; 54(4):782-7. PubMed ID: 19635982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma.
    Imayama I; Ichiki T; Inanaga K; Ohtsubo H; Fukuyama K; Ono H; Hashiguchi Y; Sunagawa K
    Cardiovasc Res; 2006 Oct; 72(1):184-90. PubMed ID: 16938288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of AMPK/proteasome/MLCK degradation signaling axis by telmisartan inhibits VSMC contractility and vessel contraction.
    Hwang YJ; Cho DH
    Biochem Biophys Res Commun; 2020 Apr; 524(4):853-860. PubMed ID: 32046856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.